Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells

Fadraciclib (CYC065) is a second-generation aminopurine CDK2/9 inhibitor with increased potency and selectivity toward CDK2 and CDK9 compared to seliciclib (R-roscovitine). In chronic lymphocytic leukemia (CLL), a disease that depends on the over-expression of anti-apoptotic proteins for its surviva...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Rong, Chen, Yuling, Xiong, Ping, Zheleva, Daniella, Blake, David, Keating, Michael J., Wierda, William G., Plunkett, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162916/
https://www.ncbi.nlm.nih.gov/pubmed/35383271
http://dx.doi.org/10.1038/s41375-022-01553-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9162916/
https://www.ncbi.nlm.nih.gov/pubmed/35383271
http://dx.doi.org/10.1038/s41375-022-01553-w

Ejemplares similares